<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03378427</url>
  </required_header>
  <id_info>
    <org_study_id>2017-001238-24</org_study_id>
    <nct_id>NCT03378427</nct_id>
  </id_info>
  <brief_title>Tedizolid Prolonged Treatment for Prosthetic Joint Infections</brief_title>
  <acronym>TEDIZOAM</acronym>
  <official_title>Prospective Cohort Study on Patients With Tedizolid Prolonged Therapy for Orthopedic Device Infections</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tourcoing Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eric SENNEVILLE M.D. Ph.D.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Tourcoing Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pilot study the aim of which is to obtain reliable data on the tolerance, compliance and
      efficacy of Tedizolid used as prolonged (≥ 6 weeks) monotherapy or in combination therapy for
      the treatment of patients with orthopedic device infections due to Gram positive cocci.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: The antibiotic treatment of patients with orthopedic device infections (e.g.
      prosthetic joint and osteosynthesis) is limited by the tolerance of prolonged administration
      of antibiotics and the high level of antibiotic resistance of some pathogens.

      The prolonged intravenous administration of antibiotics exposes the patients to the
      occurrence of adverse events and it is generally recommended to favor oral treatment provided
      high oral bioavailable agents can be used with regard to the patient's characteristics and
      the antibiotic susceptibility profile of the pathogens.

      Gram positive cocci especially coagulase negative staphylococci (CoNS) are predominant
      bacteria responsible for orthopedic device infections. The use of the oxazolidinone agent
      Linezolid in these settings has been validated by some studies in particular in combination
      with Rifampin but both hematologic, neurologic and metabolic potential toxicity limits
      treatment durations of more than two to three weeks. The risk of drug-drug interaction with
      any product having a mono-amine-oxydase inhibitor (MAOI) activity is another limiting problem
      with Linezolid use.

      In addition, the wide use of Linezolid has resulted in the emergence of CoNS carrying cfr
      genes responsible for high levels of Linezolid resistance. This is unfortunate as in many
      cases there is almost no other alternative for the oral treatment of orthopedic device
      infections due to these strains.

      Tedizolid intrinsic properties may improve the oxazolidinone treatment long term safety. Plus
      tedizolid should be active on CoNS strains resistant to linezolid.

      Objectives: Obtain reliable data on the tolerance, compliance and efficacy of Tedizolid used
      as prolonged (≥ 6 weeks) monotherapy or in combination therapy for the treatment of patients
      with orthopedic device infections due to Gram positive cocci.

      Hypothesis: As no data are currently available on long term safety of Tedizolid treatment,
      the investigators will compare the results of the present study regarding tolerance and
      efficacy with those of a historical cohort of comparable patients from our cohorts treated
      with Linezolid monotherapy or combination therapy for equivalent indications (data published
      in Journal of Antimicrobial Chemotherapy Legout L et al..2010).

      Study Design: Prospective multicenter cohort study.

      The objectives of the study are :

      (i) to assess the tolerance of TEDIZOLID determined by the proportion of patients who
      experienced any adverse event attributable to TEDIZOLID during treatment and during 6 weeks
      after the antibiotic treatment, and (ii) to assess the efficacy of TEDIZOLID as single agent
      treatment or combined therapy for orthopedic infections due to TEDIZOLID susceptible bacteria
      determined by the proportion of patient with remission of the infection (i.e. absence of any
      local and systemic sign of infection in relation with the initial infection, any surgery for
      an infectious reason at the initial site or death related to the initial infection)
      determined one year after the end of the antibiotic treatment.

      Microbiologic data from failure cases will be recorded in order to assess the presence of
      Tedizolid-resistant strains, relapsing infections, or superinfection.

      Treatment: Tedizolid 200 mg once a day, administered orally for the entire treatment will be
      prescribed in patients after the definite culture results of peroperative samples will be
      available.

      Daily doses of the antibiotics associated with tedizolid will be at the discretion of the
      clinician and will have to follow the institutional therapeutical protocols.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 15, 2018</start_date>
  <completion_date type="Anticipated">January 15, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 15, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Pilot study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bone marrow toxicity</measure>
    <time_frame>From date of inclusion until 12 months after the end of treatment</time_frame>
    <description>assessed on the values of hemoglobin, leucocytes, neutrophils and platelets counts, will be collected to determine the number of adverse event likely to be related to tedizolid treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Peripheral neuropathy</measure>
    <time_frame>From date of inclusion until 12 months after the end of treatment</time_frame>
    <description>Paresthesia, dysesthesia, hypoesthesia, allodynia (confirmed by EMG examination), will be collected to determine the number of adverse event likely to be related to tedizolid treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Metabolic acidosis</measure>
    <time_frame>From date of inclusion until 12 months after the end of treatment</time_frame>
    <description>dyspnea of unknown origin ; pH &lt; 7.35 ; [ HCO3− ] &lt; 22 mmol/L ; paCO2 &lt; 45 mmHg ; lactates &gt; 2 mmol/L, will be collected to determine the number of adverse event likely to be related to tedizolid treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serotoninergic syndrome</measure>
    <time_frame>From date of inclusion until 12 months after the end of treatment</time_frame>
    <description>will be collected to determine the number of adverse event likely to be related to tedizolid treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Retrobulbar optic nevritis</measure>
    <time_frame>From date of inclusion until 12 months after the end of treatment</time_frame>
    <description>will be collected to determine the number of adverse event likely to be related to tedizolid treatment.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Prosthetic Joint Infection</condition>
  <arm_group>
    <arm_group_label>Tedizolid Phosphate 200 MG [Sivextro]</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All included patients will receive prolonged (&gt;= 6 weeks) tedizolid treatment given orally.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tedizolid Phosphate 200 MG [Sivextro]</intervention_name>
    <description>Antibiotic treatment (monotherapy or combination) targeting bacteria cultured from per operative samples.</description>
    <arm_group_label>Tedizolid Phosphate 200 MG [Sivextro]</arm_group_label>
    <other_name>rifampin</other_name>
    <other_name>ofloxacin</other_name>
    <other_name>levofloxacin</other_name>
    <other_name>fusidic acid</other_name>
    <other_name>clindamycin</other_name>
    <other_name>teicoplanin</other_name>
    <other_name>ciprofloxacin</other_name>
    <other_name>trimethoprim-sulfamethoxazole</other_name>
    <other_name>doxycycline</other_name>
    <other_name>minocycline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient at least 18 years;

          -  Orthopedic device infection defined according to the French recommendations published
             in 2009 (Med Mal Infect 2009; 39:745-774) for which TEDIZOLID treatment is proposed
             according to the investigator's decision;

          -  Bacterial documentation of the infection will only be based on the results of reliable
             samples such as joint aspiration and peroperative samples.

          -  Requiring TEDIZOLID administration as a single antibiotic therapy or in combination
             therapy including another agent with proven activity against the involved pathogen(s);

          -  No contraindication to TEDIZOLID;

          -  Provide a signed informed consent for the trial.

        Exclusion Criteria:

          -  pregnant women or of childbearing age without contraception, breastfeeding,

          -  intolerance to TEDIZOLID;

          -  allergy to LINEZOLID;

          -  bactéria non susceptible to TEDIZOLID;

          -  patient with uncertainty regarding the possibility to achieve one-year follow-up after
             the end of treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric SENNEVILLE, M.D. Ph. D.</last_name>
    <role>Study Chair</role>
    <affiliation>G. Dron Hospital, Tourcoing, France</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eric SENNEVILLE, M.D. Ph. D.</last_name>
    <phone>+33 (0)3 20 69 46 17</phone>
    <email>esenneville@ch-tourcoing.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sylvie VANDAMME, ARC</last_name>
    <phone>+33 (0)3 20 69 46 17</phone>
    <email>svandamme@ch-tourcoing.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>GHU Garches</name>
      <address>
        <city>Garches</city>
        <zip>92380</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Aurélien DINH, M.D.</last_name>
      <phone>+33 (0)1 47 10 77 58</phone>
      <email>aurelien.dinh@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital de la Croix Rousse</name>
      <address>
        <city>Lyon</city>
        <zip>69004</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tristan FERRY, M.D. Ph. D.</last_name>
      <phone>+33 (0)4 72 07 17 55</phone>
      <email>tristan.ferry@univ-lyon1.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <results_reference>
    <citation>Titécat M, Senneville E, Wallet F, Dezèque H, Migaud H, Courcol RJ, Loïez C. Microbiologic profile of Staphylococci isolated from osteoarticular infections: evolution over ten years. Surg Infect (Larchmt). 2015 Feb;16(1):77-83. doi: 10.1089/sur.2013.258. Epub 2015 Feb 4.</citation>
    <PMID>25650692</PMID>
  </results_reference>
  <results_reference>
    <citation>Titécat M, Senneville E, Wallet F, Dezèque H, Migaud H, Courcol RJ, Loïez C. Bacterial epidemiology of osteoarticular infections in a referent center: 10-year study. Orthop Traumatol Surg Res. 2013 Oct;99(6):653-8. doi: 10.1016/j.otsr.2013.02.011. Epub 2013 Aug 27.</citation>
    <PMID>23988422</PMID>
  </results_reference>
  <results_reference>
    <citation>Pulcini C, Couadau T, Bernard E, Lorthat-Jacob A, Bauer T, Cua E, Mondain V, Chichmanian RM, Dellamonica P, Roger PM. Adverse effects of parenteral antimicrobial therapy for chronic bone infections. Eur J Clin Microbiol Infect Dis. 2008 Dec;27(12):1227-32. doi: 10.1007/s10096-008-0570-y. Epub 2008 Sep 26.</citation>
    <PMID>18818959</PMID>
  </results_reference>
  <results_reference>
    <citation>Spellberg B, Lipsky BA. Systemic antibiotic therapy for chronic osteomyelitis in adults. Clin Infect Dis. 2012 Feb 1;54(3):393-407. doi: 10.1093/cid/cir842. Epub 2011 Dec 12. Review.</citation>
    <PMID>22157324</PMID>
  </results_reference>
  <results_reference>
    <citation>Morata L, Tornero E, Martínez-Pastor JC, García-Ramiro S, Mensa J, Soriano A. Clinical experience with linezolid for the treatment of orthopaedic implant infections. J Antimicrob Chemother. 2014 Sep;69 Suppl 1:i47-52. doi: 10.1093/jac/dku252. Review.</citation>
    <PMID>25135090</PMID>
  </results_reference>
  <results_reference>
    <citation>Morata L, Senneville E, Bernard L, Nguyen S, Buzelé R, Druon J, Tornero E, Mensa J, Soriano A. A Retrospective Review of the Clinical Experience of Linezolid with or Without Rifampicin in Prosthetic Joint Infections Treated with Debridement and Implant Retention. Infect Dis Ther. 2014 Dec;3(2):235-43. doi: 10.1007/s40121-014-0032-z. Epub 2014 Aug 20.</citation>
    <PMID>25139552</PMID>
  </results_reference>
  <results_reference>
    <citation>Senneville E, Legout L, Valette M, Yazdanpanah Y, Beltrand E, Caillaux M, Migaud H, Mouton Y. Effectiveness and tolerability of prolonged linezolid treatment for chronic osteomyelitis: a retrospective study. Clin Ther. 2006 Aug;28(8):1155-1163. doi: 10.1016/j.clinthera.2006.08.001.</citation>
    <PMID>16982292</PMID>
  </results_reference>
  <results_reference>
    <citation>Senneville E, Legout L, Valette M, Yazdanpanah Y, Giraud F, Beltrand E, Obert G, Dubreuil L, Migaud H, Mouton Y. Risk factors for anaemia in patients on prolonged linezolid therapy for chronic osteomyelitis: a case-control study. J Antimicrob Chemother. 2004 Oct;54(4):798-802. Epub 2004 Aug 25.</citation>
    <PMID>15329363</PMID>
  </results_reference>
  <results_reference>
    <citation>Legout L, Senneville E, Gomel JJ, Yazdanpanah Y, Mouton Y. Linezolid-induced neuropathy. Clin Infect Dis. 2004 Mar 1;38(5):767-8.</citation>
    <PMID>14986270</PMID>
  </results_reference>
  <results_reference>
    <citation>Legout L, Valette M, Dezeque H, Nguyen S, Lemaire X, Loïez C, Caillaux M, Beltrand E, Dubreuil L, Yazdanpanah Y, Migaud H, Senneville E. Tolerability of prolonged linezolid therapy in bone and joint infection: protective effect of rifampicin on the occurrence of anaemia? J Antimicrob Chemother. 2010 Oct;65(10):2224-30. doi: 10.1093/jac/dkq281. Epub 2010 Jul 29.</citation>
    <PMID>20675299</PMID>
  </results_reference>
  <results_reference>
    <citation>Betriu C, Morales G, Rodríguez-Avial I, Culebras E, Gómez M, López-Fabal F, Picazo JJ. Comparative activities of TR-700 (torezolid) against staphylococcal blood isolates collected in Spain. Antimicrob Agents Chemother. 2010 May;54(5):2212-5. doi: 10.1128/AAC.01653-09. Epub 2010 Feb 22.</citation>
    <PMID>20176900</PMID>
  </results_reference>
  <results_reference>
    <citation>Douros A, Grabowski K, Stahlmann R. Drug-drug interactions and safety of linezolid, tedizolid, and other oxazolidinones. Expert Opin Drug Metab Toxicol. 2015;11(12):1849-59. doi: 10.1517/17425255.2015.1098617. Epub 2015 Oct 12. Review. Erratum in: Expert Opin Drug Metab Toxicol. 2015;11(12):v.</citation>
    <PMID>26457865</PMID>
  </results_reference>
  <results_reference>
    <citation>Flanagan SD, Bien PA, Muñoz KA, Minassian SL, Prokocimer PG. Pharmacokinetics of tedizolid following oral administration: single and multiple dose, effect of food, and comparison of two solid forms of the prodrug. Pharmacotherapy. 2014 Mar;34(3):240-50. doi: 10.1002/phar.1337. Epub 2013 Aug 7.</citation>
    <PMID>23926058</PMID>
  </results_reference>
  <results_reference>
    <citation>Flanagan S, McKee EE, Das D, Tulkens PM, Hosako H, Fiedler-Kelly J, Passarell J, Radovsky A, Prokocimer P. Nonclinical and pharmacokinetic assessments to evaluate the potential of tedizolid and linezolid to affect mitochondrial function. Antimicrob Agents Chemother. 2015 Jan;59(1):178-85. doi: 10.1128/AAC.03684-14. Epub 2014 Oct 20.</citation>
    <PMID>25331703</PMID>
  </results_reference>
  <results_reference>
    <citation>Lodise TP, Bidell MR, Flanagan SD, Zasowski EJ, Minassian SL, Prokocimer P. Characterization of the haematological profile of 21 days of tedizolid in healthy subjects. J Antimicrob Chemother. 2016 Sep;71(9):2553-8. doi: 10.1093/jac/dkw206. Epub 2016 Jun 17.</citation>
    <PMID>27317442</PMID>
  </results_reference>
  <results_reference>
    <citation>Schmidt-Malan SM, Greenwood Quaintance KE, Karau MJ, Patel R. In vitro activity of tedizolid against staphylococci isolated from prosthetic joint infections. Diagn Microbiol Infect Dis. 2016 May;85(1):77-9. doi: 10.1016/j.diagmicrobio.2016.01.008. Epub 2016 Jan 12.</citation>
    <PMID>26906190</PMID>
  </results_reference>
  <results_reference>
    <citation>Morata L, Mensa J, Soriano A. New antibiotics against gram-positives: present and future indications. Curr Opin Pharmacol. 2015 Oct;24:45-51. doi: 10.1016/j.coph.2015.07.004. Epub 2015 Jul 30. Review. Erratum in: Curr Opin Pharmacol. 2015 Oct;24:147.</citation>
    <PMID>26232669</PMID>
  </results_reference>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 24, 2017</study_first_submitted>
  <study_first_submitted_qc>December 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 19, 2017</study_first_posted>
  <last_update_submitted>December 18, 2017</last_update_submitted>
  <last_update_submitted_qc>December 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tedizolid</keyword>
  <keyword>Adverse effects</keyword>
  <keyword>Efficacy</keyword>
  <keyword>prosthetic joint infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Arthritis, Infectious</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ciprofloxacin</mesh_term>
    <mesh_term>Levofloxacin</mesh_term>
    <mesh_term>Trimethoprim, Sulfamethoxazole Drug Combination</mesh_term>
    <mesh_term>Torezolid</mesh_term>
    <mesh_term>Torezolid phosphate</mesh_term>
    <mesh_term>Fusidic Acid</mesh_term>
    <mesh_term>Trimethoprim</mesh_term>
    <mesh_term>Sulfamethoxazole</mesh_term>
    <mesh_term>Oxazolidinones</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

